MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

Current stock price

2.77 USD
-0.05 (-1.77%)
At close:
2.78 USD
+0.01 (+0.36%)
After Hours:

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • MNKD had positive earnings in the past year.
  • In the past year MNKD had a positive cash flow from operations.
  • In multiple years MNKD reported negative net income over the last 5 years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of MNKD (0.85%) is better than 88.05% of its industry peers.
  • MNKD's Return On Invested Capital of 7.96% is amongst the best of the industry. MNKD outperforms 92.68% of its industry peers.
  • MNKD had an Average Return On Invested Capital over the past 3 years of 10.85%. This is significantly below the industry average of 19.44%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • MNKD has a Profit Margin of 1.92%. This is amongst the best in the industry. MNKD outperforms 88.25% of its industry peers.
  • MNKD has a Operating Margin of 16.59%. This is amongst the best in the industry. MNKD outperforms 93.06% of its industry peers.
  • With an excellent Gross Margin value of 77.80%, MNKD belongs to the best of the industry, outperforming 84.20% of the companies in the same industry.
  • MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

3

2. MNKD Health Analysis

2.1 Basic Checks

  • MNKD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • MNKD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MNKD has more shares outstanding
  • Compared to 1 year ago, MNKD has a worse debt to assets ratio.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -4.17, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
  • MNKD has a Altman-Z score of -4.17. This is comparable to the rest of the industry: MNKD outperforms 40.27% of its industry peers.
  • MNKD has a debt to FCF ratio of 44.51. This is a negative value and a sign of low solvency as MNKD would need 44.51 years to pay back of all of its debts.
  • MNKD has a better Debt to FCF ratio (44.51) than 89.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.17
ROIC/WACC0.97
WACC8.17%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 1.70 indicates that MNKD should not have too much problems paying its short term obligations.
  • MNKD has a worse Current ratio (1.70) than 79.38% of its industry peers.
  • MNKD has a Quick Ratio of 1.50. This is a normal value and indicates that MNKD is financially healthy and should not expect problems in meeting its short term obligations.
  • MNKD has a Quick ratio of 1.50. This is amonst the worse of the industry: MNKD underperforms 80.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

6

3. MNKD Growth Analysis

3.1 Past

  • MNKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.75%.
  • MNKD shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.23%.
  • The Revenue has been growing by 39.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.44% on average per year.
  • MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.70% yearly.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 46.17, MNKD can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 90.17% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of MNKD to the average of the S&P500 Index (25.70), we can say MNKD is valued expensively.
  • The Price/Forward Earnings ratio is 52.00, which means the current valuation is very expensive for MNKD.
  • Based on the Price/Forward Earnings ratio, MNKD is valued cheaper than 90.37% of the companies in the same industry.
  • MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 46.17
Fwd PE 52
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaper than 94.03% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 62.34
EV/EBITDA 16.73
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • MNKD has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

0

5. MNKD Dividend Analysis

5.1 Amount

  • MNKD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (3/13/2026, 8:00:02 PM)

After market: 2.78 +0.01 (+0.36%)

2.77

-0.05 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change3.51%
Ins Owners1.57%
Ins Owner Change2.26%
Market Cap853.44M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts85.33
Price Target9.8 (253.79%)
Short Float %8.8%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-33.3%
EPS NQ rev (3m)0%
EPS NY rev (1m)-38.97%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)7.18%
Revenue NQ rev (3m)9.23%
Revenue NY rev (1m)7.09%
Revenue NY rev (3m)9.77%
Valuation
Industry RankSector Rank
PE 46.17
Fwd PE 52
P/S 2.45
P/FCF 62.34
P/OCF 46.75
P/B N/A
P/tB N/A
EV/EBITDA 16.73
EPS(TTM)0.06
EY2.17%
EPS(NY)0.05
Fwd EY1.92%
FCF(TTM)0.04
FCFY1.6%
OCF(TTM)0.06
OCFY2.14%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.17
F-Score5
WACC8.17%
ROIC/WACC0.97
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year34.43%
Revenue Next 2Y25.13%
Revenue Next 3Y18.13%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD Fundamental Analysis FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 46.17 and the Price/Book (PB) ratio is -16.73.